Join Growin Stock Community!

Spyre therapeutics, inc.SYRE.US Overview

US StockHealthcare
(No presentation for SYRE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SYRE AI Insights

SYRE Overall Performance

SYRE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SYRE Recent Performance

-2.37%

Spyre therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SYRE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SYRE Key Information

SYRE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SYRE Profile

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Price of SYRE

SYRE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SYRE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
650.22
PB Ratio
6.04
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.57
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
650.22
PB Ratio
6.04
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is SYRE's latest earnings report released?

    The most recent financial report for Spyre therapeutics, inc. (SYRE) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SYRE's short-term business performance and financial health. For the latest updates on SYRE's earnings releases, visit this page regularly.

  • How much cash does SYRE have?

    At the end of the period, Spyre therapeutics, inc. (SYRE) held Total Cash and Cash Equivalents of 85.72M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does SYRE go with three margins increasing?

    In the latest report, Spyre therapeutics, inc. (SYRE) did not achieve the “three margins increasing” benchmark, with a gross margin of 50%%, operating margin of -63.18%%, and net margin of -69.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess SYRE's profit trajectory and future growth potential.

  • Is SYRE's EPS continuing to grow?

    According to the past four quarterly reports, Spyre therapeutics, inc. (SYRE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.74. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SYRE?

    Spyre therapeutics, inc. (SYRE)'s Free Cash Flow (FCF) for the period is -44.58M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 19.84% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of SYRE?

    The latest valuation data shows Spyre therapeutics, inc. (SYRE) has a Price-To-Earnings (PE) ratio of -19.13 and a Price/Earnings-To-Growth (PEG) ratio of -0.13. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.